WASHINGTON — Several drug companies are considering “substantial and material decreases” in the prices for their drugs, Health and Human Services Secretary Alex Azar said at a congressional hearing Tuesday.
“There are actually several drug companies that are looking at substantial and material decreases in drug prices, in competitive classes, and actually competing with each other and looking to do that,” Azar said, declining to name the specific companies or products.
There is complete misconception that the drug makers and PBMs will lower drug prices. Why should they? They do have an opportunity but no one wants to kill a golden goose.
Opportunities to Lower Drug Prices and Improve Affordability: From Creation (Manufacturing) to Consumption (Patient)
Good luck. Only price controls will work and that will be resisted.
Comments are closed.